StockSelector.com
  Research, Select, & Monitor Sunday, July 05, 2020 5:23:06 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Cymabay Therapeutics, Inc.$3.50($.07)(1.96%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Cymabay Therapeutics, Inc. has an overall rank of 2057 out of 7554 stocks based on 7 positive rankings and 7 negative rankings.

Positive Rankings
Target Prices
The average analysts' target price is $10.00 for Cymabay Therapeutics using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Cymabay Therapeutics is ranked 30.
Low vPut/Call
Cymabay Therapeutics has a low Put/Call ratio of 0.03 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cymabay Therapeutics is ranked 72.
Debt-to-Equity
Cymabay Therapeutics rank is 172
90 Day Gain
Cymabay Therapeutics rank is 237
Oversold Stochastics
Cymabay Therapeutics rank is 654
Up EPS Surprise
Cymabay Therapeutics beat the consensus earnings estimate when it last reported quarterly earnings.
Price-to-Book
Cymabay Therapeutics rank is 2047
Negative Rankings
Down Ratings Revision
During the past month, the average analyst's rating or recommendation has decreased. Among companies that have been downgraded within the past month, Cymabay Therapeutics is ranked 430.
Negative ROA
Cymabay Therapeutics rank is 554
Negative ROE
Cymabay Therapeutics rank is 652
High Put/Call
Cymabay Therapeutics has a high Put/Call ratio of 0.96 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Cymabay Therapeutics is ranked 688.
Negative Cash Growth
Cymabay Therapeutics rank is 968
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Cymabay Therapeutics is ranked 1140.
10 Day Loss
Cymabay Therapeutics rank is 1541







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2020 StockSelector.com. All rights reserved.